Drug updated on 4/17/2024
| Dosage Form | Injection (intravenous; 350 mg/7 mL) |
| Drug Class | Bispecific EGF receptor-directed and MET receptor-directed antibodies |
| Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- For the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy.
Product Monograph / Prescribing Information
| Document Title | Year | Source |
|---|---|---|
| Rybrevant (amivantamab-vmjw) Prescribing Information. | 2022 | Janssen Biotech, Inc., Horsham, PA |